首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >Evaluation of effectiveness of rupatadine and olopatadine in patients of allergic rhinitis at Indore: a randomized control trial
【24h】

Evaluation of effectiveness of rupatadine and olopatadine in patients of allergic rhinitis at Indore: a randomized control trial

机译:印多尔过敏性鼻炎患者中卢帕他定和奥洛他定的疗效评估:一项随机对照试验

获取原文
获取外文期刊封面目录资料

摘要

Background: Allergic rhinitis (AR) is one of the most prevalent atopic disorders that affect productivity and quality of life. Although individually olopatadine and rupatadine are efficacious in AR, data on the head to head study of these drugs in Indian population are scanty, so present study was undertaken with an aim to compare the efficacy, safety, and cost effectiveness of rupatadine and olopatadine in patients’ of allergic rhinitis. Methods: A prospective, randomized, double blind, parallel group, comparative 2 weeks clinical study conducted in eighty patients of AR in the Department of Pharmacology, Index Medical College Hospital and Research Centre, Indore. Following inclusion and exclusion criteria, 67 patients were recruited and randomized to two treatment groups and received the respective drugs for 2 weeks. At follow-up, parameters assessed were total nasal symptom score (TNSS), change in total and differential count of eosinophil. Results: In olopatadine group, there was a significantly higher reduction in TNSS (P < 0.05) than that of rupatadine. Both the drugs significantly reduced the absolute eosinophil count, but olopatadine (P <0.001) was found to be superior. The incidence of adverse effects was found to be less in olopatadine group when compared with rupatadine group. Conclusions: Both rupatadine and olopatadine provide effective relief of the symptoms of AR. However, clinical benefit occurs significantly more with olopatadine. However, rupatadine was more cost?effective than olopatadine in treating the patients of AR in term of effectiveness.
机译:背景:过敏性鼻炎(AR)是最普遍的特应性疾病之一,会影响生产力和生活质量。尽管奥洛他定和卢帕他定在AR中是有效的,但在印度人群中这些药物的正面研究数据很少,因此,本研究旨在比较卢帕他定和奥洛他定在患者中的疗效,安全性和成本效益过敏性鼻炎。方法:前瞻性,随机,双盲,平行组,在印多尔索引医学院附属医院和研究中心药理学系对80例AR患者进行了为期2周的比较临床研究。根据纳入和排除标准,招募了67名患者,并将其随机分为两个治疗组,并分别接受了2周的药物治疗。随访时,评估的参数为总鼻症状评分(TNSS),嗜酸性粒细胞总数和差异计数的变化。结果:在奥洛他定组中,TNSS的降低显着高于卢帕他定(P <0.05)。两种药物均显着降低了嗜酸性粒细胞的绝对计数,但发现奥洛他定(P <0.001)更好。与奥帕他定组相比,奥洛他定组的不良反应发生率更低。结论:卢帕他定和奥洛他定均可有效缓解AR症状。但是,奥洛他定的临床获益明显更多。然而,就有效性而言,卢帕他定比奥洛他定在成本上更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号